Abbisko Cayman Reports Positive Phase II Results for Oral PD-L1 Inhibitor ABSK043 in NSCLC Combination Therapy
Abbisko Cayman Limited announced the preliminary results from the dose escalation phase of its ongoing Phase II clinical study evaluating the oral small-molecule PD-L1 inhibitor ABSK043 in combination with the third-generation EGFR-TKI, firmonertinib, for the treatment of non-small cell lung cancer (NSCLC). The data, presented at the European Society for Medical Oncology Asia Congress 2025 (ESMO Asia 2025), indicated that the combination therapy demonstrated favorable safety and tolerability. Regulatory authorities have agreed to expand the program into a first-line study in treatment-naïve patients with EGFR mutated, PD-L1 positive NSCLC. Abbisko Cayman Limited noted that there is no guarantee that ABSK043 will ultimately be successfully marketed.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Abbisko Cayman Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251208-11947313), on December 08, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。